Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.
The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.
Perspective Therapeutics, Inc. describes its business as a clinical-stage radiopharmaceutical company developing precision targeted alpha therapies for cancer. Its platform centers on Lead‑212 (212Pb) therapeutics paired with Lead‑203 (203Pb) imaging to personalize treatment and limit damage to healthy tissue.
The company’s lead programs target neuroendocrine tumors (VMT‑α‑NET), metastatic melanoma (VMT01) and FAP‑α–expressing solid tumors (PSV359), all in Phase 1/2a trials. It highlights Fast Track designations, early clinical signals, and a 2024 option and funding agreement with an affiliate of Lantheus for VMT‑α‑NET and earlier PSMA/GRPR assets.
Perspective is building a distributed manufacturing network using proprietary 212Pb generators, facilities in Iowa and New Jersey, and new sites in Houston, Chicago and Los Angeles. The filing emphasizes substantial ongoing losses, the need for significant additional capital, clinical, regulatory and manufacturing risks, and stock price volatility. As of March 12, 2026, common shares outstanding were 113,933,436.
Perspective Therapeutics reported a larger net loss for 2025 while advancing its radiopharmaceutical pipeline and strengthening its balance sheet. Net loss was $103.1 million, or $1.40 per share, compared with $79.3 million, or $1.23 per share in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $84.2 million, up about 102%, as the company expanded clinical activities for its VMT-α-NET, VMT01 and PSV359 programs and recorded a $10.0 million non-cash impairment on a deprioritized preclinical asset. General and administrative expenses increased to $30.2 million from $26.6 million.
Cash, cash equivalents and short-term investments were about $145 million as of December 31, 2025, down from $227 million a year earlier. In February 2026, the company closed an underwritten equity offering with net proceeds of approximately $164 million, and now expects its cash resources to fund planned clinical milestones and operations into late 2027.
Perspective Therapeutics, Inc. ownership disclosure: Avidity reporting group states shared beneficial ownership of 6,049,999 shares of Common Stock, representing 5.3%.
The filing also shows Avidity Private Master Fund I LP holds 5,849,999 shares ( 5.1%). The report is signed by Michael Gregory on 03/10/2026.
Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.
Morich Frank reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.
The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.
Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Robert F. Williamson III reported receiving a grant of stock options representing 50,000 shares on March 2, 2026. The award was approved by the board on January 26, 2026 as his annual equity grant for 2026 and will vest in full on March 2, 2027, provided he continues serving through that date.
HENSON HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics director Heidi Henson was granted a stock option covering 50,000 shares on March 2, 2026. The grant was approved by the board as her annual 2026 equity award. The option vests in full on March 2, 2027, if she continues serving through that date.
Perspective Therapeutics director receives 2026 stock option grant. Director Lori A. Woods was granted a stock option to buy 50,000 shares at an exercise price of $0.0000 per share as her annual equity award for 2026. The option vests in full on March 2, 2027, assuming she continues to serve through the vesting date.
Spoor Johan M. reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. reported that Chief Executive Officer Johan M. Spoor was granted stock options covering 735,000 shares on the March 2, 2026 grant date. The award, approved by the board on January 26, 2026, represents his annual 2026 equity grant. The options vest in 48 substantially equal monthly installments starting one month after the grant date, contingent on his continued service.